The Magazine for Sleep Professionals
Friday, June 19, 2026
Dental Sleep Medicine | Sleep Disorders | Testing Modalities & Diagnostics | Patient Health | Pharmaceuticals | Research/Studies
Alkermes plc, announced the initiation of the Brilliance Studies, a phase 3 program evaluating the safety and efficacy of alixorexton compared to placebo in adults with narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2). Alixorexton is the company’s novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development […]
Eisai Inc. announced today that screening for global Study E2086-G000-202 (Study 202) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ClinicalTrials.gov as NCT07493265. Study sites are also planned for Canada, China, Europe, Japan, and South Korea. Study 202 is a three-period, […]
Eli Lilly and Company and Centessa Pharmaceuticals plc, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Lilly to acquire Centessa. Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists designed to […]
Narcolepsy is a chronic condition in which someone feels excessively sleepy, occasionally falling asleep without warning. This can have a major impact on their daily lives, affecting not only their education and employment, but also their ability to drive, their relationships, and their emotional health. “It’s quite striking when you’re […]
AI software designed to help diagnose sleep apnea in children has achieved high accuracy in an NHS trial, with the findings independently reviewed by clinical specialists. Glasgow company Seluna tested its autoscoring and sleep staging software on 500 retrospective sleep studies from NHS Greater Glasgow and Clyde’s Royal Hospital for […]
LivaNova PLC announced the U.S. Food and Drug Administration (FDA) granted premarket approval (PMA) for the aura6000™ System for the treatment of adult patients with moderate to severe Obstructive Sleep Apnea (OSA). The System utilizes proximal hypoglossal nerve stimulation (p-HGNS), a differentiated neurostimulation modality, to treat OSA in patients with […]
Wesper announces Robert Wood Johnson University Hospital (RWJUH) Somerset has expanded monthly sleep testing capacity by 290% following the adoption of Wesper’s direct-to-patient, dropship home sleep testing model, according to a newly released whitepaper detailing the operational transformation. Prior to implementation, RWJUH Somerset faced growing demand for sleep apnea testing […]
Sunrise Group announced results from the SUNSAS clinical study, now published in The Lancet Regional Health – Europe, a leading international medical journal. Supported by the French Ministry of Health through the Forfait Innovation program, this study is the largest randomized controlled trial to date evaluating an at-home diagnostic pathway for obstructive […]
This rising demand collides with real operational constraints, such as credentialed technologists and physician shortages, aging equipment, getting out in front of evolving billing codes in 2026, and the modifications needed for the type of HST devices utilized, fragmented software, EMR integration requirements, capital constraints, and pressure to expand home‑based […]
